Newleos Therapeutics Launches with $93.5M to Develop Novel Neuropsychiatric Treatments

Newleos Therapeutics debuted with a $93.5 million Series A financing led by Goldman Sachs Alternatives12.

The company's clinical-stage pipeline was licensed from Roche and includes oral small molecules targeting novel mechanisms for neuropsychiatric disorders15.

Newleos was co-founded by Longwood Fund, Federico Bolognani, M.D., Ph.D., and William Martin, Ph.D5.

The lead clinical program, NTX-1955, is a first-in-class GABA A -γ1 selective positive allosteric modulator designed to treat anxiety disorders5.

Newleos plans to conduct proof-of-concept clinical trials across its programs, focusing on conditions such as generalized anxiety, social anxiety, substance use disorders, and cognitive impairment25.

The company aims to address the high unmet need in neuropsychiatric disorders, which affect over 60 million individuals in the US5.

Investors in the Series A round include Novo Holdings A/S, Longwood Fund, DCVC Bio, and Arkin Bio Capital12.

Newleos is based in Boston and plans to have up to 20 team members by the end of 20253.

Sources:

1. https://sfbn.org/san-francisco-biotech-news/2025/02/13/vc-longwood-fund-unveils-neuro-biotech-with-93m-assets-licensed-from-roche/

2. https://www.fiercebiotech.com/biotech/longwood-fund-unveils-neuro-biotech-93m-assets-licensed-roche

3. https://www.bizjournals.com/boston/news/2025/02/13/newleos-therapeutics-launches-longwood-fund.html

5. https://www.businesswire.com/news/home/20250213253174/en/Newleos-Therapeutics-Debuts-with-93.5-Million-Oversubscribed-Series-A-Financing-to-Transform-the-Treatment-of-Neuropsychiatric-Disorders-through-the-Advancement-of-Novel-Medicines